MedTrace Logo

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

NCT02436928 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-08-22

No results posted yet for this study

Summary

This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.

Conditions

  • H7N9 Influenza Vaccine

Interventions

BIOLOGICAL

AT-501 High Dose vaccine

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 High Dose vaccine with Adjuvant

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 Low Dose vaccine

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 Low Dose vaccine with Adjuvant

Comparison of each dose of vaccine

Sponsors & Collaborators

  • Medigen Vaccine Biologics Corp.

    lead INDUSTRY

Principal Investigators

  • Shan-Chwen Chang, Dr. · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436928 on ClinicalTrials.gov